Lv6
2200 积分 2021-04-14 加入
Exploring clinical factors to predict the survival for resectable non-small cell lung cancer patients with neoadjuvant immunotherapy
11天前
已完结
Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Resectable Non–small Cell Lung Cancer Treated With Neoadjuvant Immunotherapy Plus Chemotherapy
11天前
已完结
An all-in-one polymeric nanomedicine as in situ cascade cancer vaccine for potent cancer immunotherapy
1个月前
已完结
Facts and hopes in neoadjuvant immunotherapy combinations in resectable non-small-cell lung cancer
2个月前
已完结
Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY)
3个月前
已完结
[Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China (2024 version)]
3个月前
已完结
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
3个月前
已完结
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
3个月前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
3个月前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已关闭
皖公网安备34019202002308
